Celon Pharma Statistics

Total Valuation

Celon Pharma has a market cap or net worth of PLN 1.17 billion. The enterprise value is 1.14 billion.

Market Cap	1.17B
Enterprise Value	1.14B

Important Dates

The next estimated earnings date is Tuesday, September 23, 2025.

Earnings Date	Sep 23, 2025
Ex-Dividend Date	Jun 27, 2024

Share Statistics

Celon Pharma has 53.86 million shares outstanding. The number of shares has increased by 4.01% in one year.

Current Share Class	38.86M
Shares Outstanding	53.86M
Shares Change (YoY)	+4.01%
Shares Change (QoQ)	+8.90%
Owned by Insiders (%)	0.01%
Owned by Institutions (%)	21.09%
Float	23.82M

Valuation Ratios

PE Ratio	n/a
Forward PE	22.78
PS Ratio	5.43
PB Ratio	2.79
P/TBV Ratio	2.83
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-25.90
EV / Sales	5.28
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-26.33

Financial Position

The company has a current ratio of 2.03, with a Debt / Equity ratio of 0.05.

Current Ratio	2.03
Quick Ratio	1.55
Debt / Equity	0.05
Debt / EBITDA	n/a
Debt / FCF	-0.46
Interest Coverage	-23.08

Financial Efficiency

Return on equity (ROE) is -10.34% and return on invested capital (ROIC) is -7.55%.

Return on Equity (ROE)	-10.34%
Return on Assets (ROA)	-6.28%
Return on Invested Capital (ROIC)	-7.55%
Return on Capital Employed (ROCE)	-12.01%
Revenue Per Employee	379,376
Profits Per Employee	-77,358
Employee Count	558
Asset Turnover	0.40
Inventory Turnover	2.32

Taxes

Income Tax	-5.16M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +42.22% in the last 52 weeks. The beta is 0.83, so Celon Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.83
52-Week Price Change	+42.22%
50-Day Moving Average	23.32
200-Day Moving Average	25.54
Relative Strength Index (RSI)	49.35
Average Volume (20 Days)	17,659

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Celon Pharma had revenue of PLN 215.11 million and -43.86 million in losses. Loss per share was -0.83.

Revenue	215.11M
Gross Profit	145.73M
Operating Income	-53.92M
Pretax Income	-49.02M
Net Income	-43.86M
EBITDA	-19.09M
EBIT	-53.92M
Loss Per Share	-0.83

Full Income Statement

Balance Sheet

The company has 52.52 million in cash and 19.79 million in debt, giving a net cash position of 32.73 million or 0.61 per share.

Cash & Cash Equivalents	52.52M
Total Debt	19.79M
Net Cash	32.73M
Net Cash Per Share	0.61
Equity (Book Value)	419.53M
Book Value Per Share	7.79
Working Capital	74.34M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -17.23 million and capital expenditures -25.92 million, giving a free cash flow of -43.15 million.

Operating Cash Flow	-17.23M
Capital Expenditures	-25.92M
Free Cash Flow	-43.15M
FCF Per Share	-0.80

Full Cash Flow Statement

Margins

Gross margin is 67.75%, with operating and profit margins of -25.07% and -20.39%.

Gross Margin	67.75%
Operating Margin	-25.07%
Pretax Margin	-22.79%
Profit Margin	-20.39%
EBITDA Margin	-8.88%
EBIT Margin	-25.07%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 0.08, which amounts to a dividend yield of 0.36%.

Dividend Per Share	0.08
Dividend Yield	0.36%
Dividend Growth (YoY)	-11.11%
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.01%
Shareholder Yield	-3.64%
Earnings Yield	-3.75%
FCF Yield	-3.69%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Celon Pharma has an Altman Z-Score of 7.31 and a Piotroski F-Score of 2.

Altman Z-Score	7.31
Piotroski F-Score	2